DnB Markets - TOMRA Systems ASA (TOM) Tomra (Sell, TP: NOK95.00) - Next stop, Poland

Report

DnB Markets

Niclas Gehin

EUR 456.78 For Business Accounts Only

Tomra (Sell, TP: NOK95.00) - Next stop, Poland

We estimate Q3 EBITA of EUR45m (results due at 07:00 CET on 22 October), with EPS of EUR0.09 (consensus EUR0.07). While we have raised our 2025–2026e EPS by 1%, we still see the stock as overvalued, as we believe its growth potential does not justify a 2024e P/E of 43x. We see downside risk to market expectations for Poland’s implementation in 2025-2026, and also the rest of EU. We reiterate our SELL and NOK95 target price.

14/10/2024 1 EN

Underlying

TOMRA Systems ASA

Tomra Systems is a creator of sensor-based solutions for optimal resource productivity within the business streams of reverse vending, material recovery, compaction, recycling, mining, and food. Co.'s operating structure comprises two business areas and six business streams. The TOMRA Collection Solutions businesss area consists of three business streams: reverse vending, material recovery, as well as compaction. The TOMRA Sorting Solutions, business area consists of three business streams: food, recycling, and mining.

See profile

NO0005668905 Oslo Bors Norway

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

Niclas Gehin

Other Reports on these Companies

SmartInsider

Tomra Systems ASA: 1 director

A director at Tomra Systems ASA bought 4,000 shares at 168.675NOK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

Free Trial

July 30, 2024 July 30, 2024 1 EN

DnB Markets

Tomra (Sell, TP: NOK95.00) - Another volatile reaction

Q2 EBITA was EUR43m, in line with our forecast but 23% above consensus, with all divisions beating consensus. EPS was EUR0.08, 6% below our estimate but 33% above consensus. With Recycling revenue lagging behind YOY, Tomra reduced its 2024 guidance to flat annual top-line growth. Our estimates are largely unchanged, and we maintain our view that Tomra’s stock price has decoupled from fundamentals. We reiterate our SELL and NOK95 target price.

Free Trial

July 19, 2024 July 19, 2024 1 EN

Elkem (Hold, TP: NOK22.00) - Silicones overcapacity still an issue

We expect group Q3 EBITDA of NOK1,078m (4% below consensus), including NOK140m from Silicones, driven by smaller improvements in the European market. However, given overcapacity in silicones, weak end-market demand and muted commodity prices, we do not expect a material earnings boost in the coming years. We reiterate our HOLD and NOK22 target price. The Q3 results are due at 07:00 CET on 24 October.

Free Trial

2h / 14m 2h / 14m 1 EN

Geir Hiller Holom

Geir Hiller Holom

Arctic Bioscience (Hold, TP: NOK15.00) - HeROPA-trial results

Arctic Bioscience announced results for the HeROPA trial (mild-to moderate psoriasis). While the results did not include detailed data, it was clear that the trial did not meet the primary endpoint (The proportion of patients with ≥50% reduction in Psoriasis Area and Severity Index (PASI50) from baseline to week 26). The failure to meet the primary endpoint was partly explained by an unexpectedly high effect rate in the placebo group (comparisons between HRO350 2,100 mg and placebo, and HRO350 1,050 mg and placebo were conducted). This is a dramatic setback for the company, in our view, since ...

Free Trial

3h / 11m 3h / 11m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Tomra (Sell, TP: NOK95.00) - Next stop, Poland

Tomra Systems ASA: 1 director

Tomra (Sell, TP: NOK95.00) - Another volatile reaction

Elkem (Hold, TP: NOK22.00) - Silicones overcapacity still an issue

Arctic Bioscience (Hold, TP: NOK15.00) - HeROPA-trial results

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe